NOW Thai HAART Study
After Initiation of HAART in peoples who living with HIV/AIDS in Thailand by the year 2000, rapidly expanded HAART access of national project has been promoted in 2004. Free ARVs (For CD4<200cell/cu.mm. or in symptomatic HIV with CD4<250 cell/cu.mm. )and CD4 monitoring has been available. The first-line regimen is d4T+3TC+NVP in mainly the first time (Naive) patients. CD4 response ), rate of opportunistic infection, and neurological outcomes were measured. Rate of ARV change, adverse events,treatment failure, TB co-infection rate, percent changing to EFV-based regimen or PI-based regimen were recorded.
Any Adverse Events including, Sever rash, Severe Hepatitis, Lipid abnormalities, Severe Anemia and Other, common AEs will be analysed.
Drug: Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI)
|Study Design:||Observational Model: Defined Population
Time Perspective: Cross-Sectional
|Official Title:||Neurological Outcomes With in THAI National HAART Program.|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00367731
|Bangkok, Thailand, 10400|
|Principal Investigator:||Subsai Kongsaengdao, M.D.||Rajavithi Hospital|